成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. PI3K/Akt/mTOR Autophagy Immunology/Inflammation Apoptosis Cell Cycle/DNA Damage Anti-infection
  3. mTOR FKBP Autophagy Apoptosis Bacterial
  4. Everolimus

Everolimus  (Synonyms: 依維莫司; RAD001; SDZ-RAD)

目錄號(hào): HY-10218 純度: 99.85%
COA 產(chǎn)品使用指南 技術(shù)支持

Everolimus (RAD001) 是一種雷帕霉素 (Rapamycin; HY-10219) 的衍生物，也是一種有效的，選擇性的和口服活性的 mTOR1 抑制劑。Everolimus 與 FKBP-12 結(jié)合可產(chǎn)生免疫抑制復(fù)合物。Everolimus 抑制腫瘤細(xì)胞增殖并誘導(dǎo)細(xì)胞凋亡 (apoptosis) 和自噬 (autophagy)。Everolimus 具有有效的免疫抑制和抗癌活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Everolimus Chemical Structure

Everolimus Chemical Structure

CAS No. : 159351-69-6

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥854
In-stock
5 mg ￥550
In-stock
10 mg ￥810
In-stock
50 mg ￥2743
In-stock
100 mg ￥4200
In-stock
500 mg 現(xiàn)貨 詢價(jià)
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Everolimus:

MCE 顧客使用本產(chǎn)品發(fā)表的 84 篇科研文獻(xiàn)

WB

    Everolimus purchased from MCE. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019.  [Abstract]

    Total proteins in tumor tissues from nude mice were extracted and the expressions of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K (Thr389) and p70S6K were evaluated by Western blot (n=5). Values represent the mean±SD.

    Everolimus purchased from MCE. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019.  [Abstract]

    ECa109 cells stably transfected with control shRNA or RICTOR shRNA were treated with RAD001 (10 μmol/L) or PP242 (2 μmol/L) for 48 h, and total proteins were extracted to analysis the expression of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K and p70S6K by Western blot (n=5).

    Everolimus purchased from MCE. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53.  [Abstract]

    Combination of Everolimus with AZD2281 (left panel) and AZD2014 with AZD2281 (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.

    Everolimus purchased from MCE. Usage Cited in: Prostate. 2019 Jan;79(1):44-53.  [Abstract]

    Treatment with sub-dose of Everolimus (10 nM), together with CQ (5 μM) increases the levels of Bax and cleaved PARP, and decreases the levels of Bcl-2 expression in both PC3 and LNPER cells.

    Everolimus purchased from MCE. Usage Cited in: Nutrients. 2018 Dec 8;10(12). pii: E1950.  [Abstract]

    Western analysis of protein expression in cells treatmented with or without PLX4032 or RAD001.

    Everolimus purchased from MCE. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111.  [Abstract]

    MT-2 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

    Everolimus purchased from MCE. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111.  [Abstract]

    ATL-43T cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

    Everolimus purchased from MCE. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111.  [Abstract]

    HUT-102 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

    Everolimus purchased from MCE. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111.  [Abstract]

    ED-40415 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

    Everolimus purchased from MCE. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19;12:911-920.  [Abstract]

    Immunoblotting demonstrates that AZD6244 can effectively restore upregulation of LC3-II/I and downregulation of p62 induced by RAD001 in 786-O and A498 cells.

    Everolimus purchased from MCE. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19;12:911-920.  [Abstract]

    786-O and A498 cell lines are treated by RAD001 with different concentrations for 24 hours. Immunoblotting shows that RAD001 induces autophagy indicators including upregulation of LC3-II/I and downregulation of p62 in a dose-dependent manner.

    Everolimus purchased from MCE. Usage Cited in: Cancer Lett. 2017 Nov 1;408:43-54.  [Abstract]

    Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM Everolimus. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.

    Everolimus purchased from MCE. Usage Cited in: Molecules. 2017 Dec 12;22(12). pii: E2207.  [Abstract]

    p-AKT level in NRK cells treated with 5 nM RAD-001, 1 μM Resveratrol and their combination for 2 h and analyzed by Western blotting. Blots from 3 independent experiments are used for quantification.

    Everolimus purchased from MCE. Usage Cited in: PLoS One. 2016 Jan 28;11(1):e0147682.  [Abstract]

    CHP-212 and SK-N-AS cells are treated with indicated concentrations of AZD6244, MEK162, Everolimus or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot. Phosphorylation levels of AKT, ERK and S6 are detected by specific anti-phospho antibodies. Loading is verified by specific antibodies to total AKT, ERK and anti-tubulin.

    Everolimus purchased from MCE. Usage Cited in: Oncotarget. 2015 Dec 8;6(39):42183-96.  [Abstract]

    KNS-62 and T24 cells are treated with 250 nM AZD6244, 250 nM MEK162, 5 nM of Everolimus, 250 nM AKT8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot.

    Everolimus purchased from MCE. Usage Cited in: Sci Transl Med. 2013 Jul 31;5(196):196ra99.  [Abstract]

    Apoptosis and PI3K/Akt/mTOR pathway inhibition in cells treated with BYL719, RAD001, or the combination. Protein lysates from HCC1954 and JIMT-1 cells treated for 18 hours with 0.5 μM BYL719, 1 nM RAD001 or the combination are analyzed by immunoblotting against the indicated proteins. Data are shown as mean ± SEM. p-value is calculated using two-sided student’s t-test.

    查看 mTOR 亞型特異性產(chǎn)品:

    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

    IC50 & Target[1]

    mTOR

    5-6 nM (IC50)

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    CAKI-1 IC50
    14 μM
    Compound: Everolimus
    Cytotoxicity against human Caki1 cells after 72 hrs by MTT assay
    Cytotoxicity against human Caki1 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    COLO 205 IC50
    20 μM
    Compound: Everolimus
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    Cortical neurone IC50
    150 pM
    Compound: RAD001
    Inhibition of oversizing of mouse primary cortical neuron harboring TSC1 deletion mutant at 20 nM incubated for 7 days by immunofluorescence assay
    Inhibition of oversizing of mouse primary cortical neuron harboring TSC1 deletion mutant at 20 nM incubated for 7 days by immunofluorescence assay
    		[PMID: 31955578]
    DU-145 IC50
    8 μM
    Compound: Everolimus
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    HCT-116 IC50
    12 μM
    Compound: Everolimus
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    HOP-62 IC50
    19 μM
    Compound: Everolimus
    Cytotoxicity against human HOP62 cells after 72 hrs by MTT assay
    Cytotoxicity against human HOP62 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    HT-29 IC50
    15 μM
    Compound: Everolimus
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    MCF7 EC50
    < 1 nM
    Compound: Everolimus
    Cytotoxicity against human MCF7 cells after 5 days by Presto blue reagent-based fluorescence analysis
    Cytotoxicity against human MCF7 cells after 5 days by Presto blue reagent-based fluorescence analysis
    		10.1039/C5MD00493D
    OVCAR-3 IC50
    16 μM
    Compound: Everolimus
    Cytotoxicity against human OVCAR3 cells after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR3 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    SK-HEP1 IC50
    12 μM
    Compound: Everolimus
    Cytotoxicity against human SKHEP1 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKHEP1 cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    SQ20B IC50
    5.5 μM
    Compound: Everolimus
    Cytotoxicity against human SQ20B cells after 72 hrs by MTT assay
    Cytotoxicity against human SQ20B cells after 72 hrs by MTT assay
    		[PMID: 24445311]
    SQ20B IC50
    7.3 μM
    Compound: RAD001
    Cytotoxicity against human SQ20B cells after 72 hrs by MTT assay
    Cytotoxicity against human SQ20B cells after 72 hrs by MTT assay
    		[PMID: 24836070]
    體外研究
    (In Vitro)

    依維莫司 (RAD001) 是一種口服活性雷帕霉素衍生物，可抑制絲氨酸/蘇氨酸激酶 mTOR[1]。
    在敏感的小鼠 B16/BL6 黑色素瘤 (IC50，0.7 nM) 和不敏感的人宮頸 KB-31 (IC50，1,778 nM) 中，抗增殖濃度的依維莫司會(huì)導(dǎo)致 S6K1 和底物 S6 完全去磷酸化，并導(dǎo)致 4E-BP1 遷移率發(fā)生變化，這表明磷酸化狀態(tài)降低[3]。
    依維莫司在 BT474 細(xì)胞系和原發(fā)性乳腺癌細(xì)胞的總細(xì)胞和干細(xì)胞中均表現(xiàn)出劑量依賴性抑制，盡管生長(zhǎng)抑制程度不同。與總細(xì)胞相比，在所有測(cè)試濃度下，依維莫司對(duì)干細(xì)胞的生長(zhǎng)抑制效果均較差（P<0.001）。依維莫司對(duì) BT474 和原代 CSC 的 IC50 值分別為 2,054 和 3,227 nM，分別是其對(duì)應(yīng)總細(xì)胞 IC50 值的 29 倍和 21 倍[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    依維莫司口服后對(duì)小鼠和大鼠均有效，可產(chǎn)生抗腫瘤作用，其特點(diǎn)是腫瘤生長(zhǎng)速度顯著降低而非消退。在大鼠 CA20498 模型中，每日服用依維莫司 (0.5 或 2.5 mg/kg) 可劑量依賴性地抑制生長(zhǎng)，而間歇性服用較高劑量 5 mg/kg (每周一次或兩次) 也顯示出類似的抗腫瘤效果。依維莫司抑制的特點(diǎn)是持續(xù)抑制而非消退，并且與體重減輕無關(guān)[1]。
    依維莫司治療 (0.1-10 mg/kg/d) 的效果具有選擇性，與 PTK/ZK (100 mg/kg) 的效果不同。無論是哪種生長(zhǎng)因子，依維莫司都會(huì)劑量依賴性地增加血紅蛋白含量（換算成血液當(dāng)量，可指示血管數(shù)量和血管滲漏），但會(huì)降低 Tie-2 含量（內(nèi)皮細(xì)胞數(shù)量，可指示血管數(shù)量），這對(duì) VEGF 刺激很重要，但對(duì) bFGF 刺激則不重要。依維莫司在小鼠體內(nèi)的藥代動(dòng)力學(xué)表明，單次給藥后，人類腫瘤異種移植中的最大濃度僅為 0.1 μM，而血漿濃度在約 4 小時(shí)內(nèi)可達(dá)到 1 至 3 μM[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    958.22

    Formula

    C53H83NO14
    CAS 號(hào)
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    依維莫司
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 50 mg/mL (52.18 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.0436 mL 5.2180 mL 10.4360 mL
    5 mM 0.2087 mL 1.0436 mL 2.0872 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (2.61 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (2.61 mM); 懸濁液; 超聲助溶

      此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.85%

    參考文獻(xiàn)
    Cell Assay
    [2]

    Tumor cells are plated into 96-well plates at densities ranging from 500 to 5,000/100 μL/well, with repeat experiments being done at an optimal cell number, typically 1,000 to 2,000 per well, and incubated overnight. Cells are exposed to Everolimus and incubated for 4 days and the cell number is determined by methylene blue staining. For this, 50 μL glutaraldehyde [20% (v/v)] is added to the wells incubated for 10 min at room temperature. The culture medium is aspirated, cells are washed with distilled water, and 100 μL methylene blue [0.05% (w/v) in water] is added and incubated for 10 min at 37°C. Stained cells are washed three times with water, 200 μL HCl [3% (v/v)] is added, and the plate shaken at room temperature for 20 min. The absorbance of each well is determined at 650 nm. The IC50 values are calculated using Softmax 2.0 software[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2]

    Mice[2]
    Everolimus, PTK/ZK, and their respective vehicles are prepared each day just before administration to animals and the administration volume is individually adjusted based on animal body weight. In C57/BL6 mice, Everolimus is administered at doses ranging from 0.1 to 10 mg/kg/d orally (10 mL/kg) and predominantly at 2.5 to 10 mg/kg because these doses provides the maximum effect. PTK/ZK is administered at 50 to 100 mg/kg/d orally.
    Rats[2]
    Wistar-Furth rats are divided into two equal groups based on body weight and treated either with vehicle or Everolimus (10 mg/kg/d orally in mice and 5 mg/kg three times per week orally in rats). Directly after the first measurement at baseline (day 0), Everolimus or vehicle is administered orally by gavage (10 mL/kg) for up to 7 days maximum with subsequent magnetic resonance measurements made within 30 min of the last dose.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.0436 mL 5.2180 mL 10.4360 mL 26.0900 mL
    5 mM 0.2087 mL 1.0436 mL 2.0872 mL 5.2180 mL
    10 mM 0.1044 mL 0.5218 mL 1.0436 mL 2.6090 mL
    15 mM 0.0696 mL 0.3479 mL 0.6957 mL 1.7393 mL
    20 mM 0.0522 mL 0.2609 mL 0.5218 mL 1.3045 mL
    25 mM 0.0417 mL 0.2087 mL 0.4174 mL 1.0436 mL
    30 mM 0.0348 mL 0.1739 mL 0.3479 mL 0.8697 mL
    40 mM 0.0261 mL 0.1305 mL 0.2609 mL 0.6523 mL
    50 mM 0.0209 mL 0.1044 mL 0.2087 mL 0.5218 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Everolimus
    目錄號(hào)：
    HY-10218
    需求量：